Cargando…

Correction: COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report

Detalles Bibliográficos
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2021
Materias:	Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8344306/ https://www.ncbi.nlm.nih.gov/pubmed/34353850 http://dx.doi.org/10.1136/jitc-2020-001870corr1

Ejemplares similares

COVID-19 lung injury as a primer for immune checkpoint inhibitors (ICIs)-related pneumonia in a patient affected by squamous head and neck carcinoma treated with PD-L1 blockade: a case report
por: Dipasquale, Angelo, et al.
Publicado: (2021)

Correction: Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
Publicado: (2023)

Combining Radiation and Immune Checkpoint Blockade in the Treatment of Head and Neck Squamous Cell Carcinoma
por: Manukian, Gregor, et al.
Publicado: (2019)

Clinical-genomic determinants of immune checkpoint blockade response in head and neck squamous cell carcinoma
por: Valero, Cristina, et al.
Publicado: (2023)

Tumor hypoxia is associated with resistance to PD-1 blockade in squamous cell carcinoma of the head and neck
por: Zandberg, Dan P, et al.
Publicado: (2021)

Characterization of the Immune Response to PD-1 Blockade during Chemoradiotherapy for Head and Neck Squamous Cell Carcinoma
por: Callejas-Valera, Juan L., et al.
Publicado: (2022)

Genomic and Molecular Profiling of Human Papillomavirus Associated Head and Neck Squamous Cell Carcinoma Treated with Immune Checkpoint Blockade Compared to Survival Outcomes
por: Shaikh, Hira, et al.
Publicado: (2021)

Current Understanding of the Mechanisms Underlying Immune Evasion From PD-1/PD-L1 Immune Checkpoint Blockade in Head and Neck Cancer
por: Kok, Victor C.
Publicado: (2020)

PD-L1 expression in the microenvironment and the response to checkpoint inhibitors in head and neck squamous cell carcinoma
por: Evrard, D., et al.
Publicado: (2020)

A Retrospective Analysis of a Cohort of Patients Treated With Immune Checkpoint Blockade in Recurrent/Metastatic Head and Neck Cancer
por: Bila, Michel, et al.
Publicado: (2022)

Performance status (PS) as a predictor of poor response to immune checkpoint inhibitors (ICI) in recurrent/metastatic head and neck cancer (RMHNSCC) patients
por: Chalker, Cameron, et al.
Publicado: (2022)

Age-Based Disparities in Metastatic Melanoma Patients Treated in the Immune Checkpoint Inhibitors (ICI) Versus Non-ICI Era: A Population-Based Study
por: Safi, Mohammed, et al.
Publicado: (2021)

Clinical characteristics and treatment efficacy of immune checkpoint inhibitors (ICIs) in patients with ICIs-induced Adrenal insufficiency
por: Xiang, Jing, et al.
Publicado: (2023)

Identification of immune‐related lncRNA panel for predicting immune checkpoint blockade and prognosis in head and neck squamous cell carcinoma
por: Li, Qun, et al.
Publicado: (2022)

Immune Checkpoints Pathways in Head and Neck Squamous Cell Carcinoma
por: Veigas, Florencia, et al.
Publicado: (2021)

Checkpoint blockade-induced CD8+ T cell differentiation in head and neck cancer responders
por: Zhou, Liye, et al.
Publicado: (2022)

Statin drugs enhance responses to immune checkpoint blockade in head and neck cancer models
por: Kansal, Vikash, et al.
Publicado: (2023)

Digital Spatial Profiling Links Beta-2-microglobulin Expression with Immune Checkpoint Blockade Outcomes in Head and Neck Squamous Cell Carcinoma
por: Gavrielatou, Niki, et al.
Publicado: (2023)

Correction: Novel Insight into Mutational Landscape of Head and Neck Squamous Cell Carcinoma
por: Gaykalova, Daria A., et al.
Publicado: (2020)

Interleukin-34 Limits the Therapeutic Effects of Immune Checkpoint Blockade
por: Hama, Naoki, et al.
Publicado: (2022)

Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier
por: Vafaei, Somayeh, et al.
Publicado: (2022)

Correction: The influence of FCGR2A and FCGR3A polymorphisms on the survival of patients with recurrent or metastatic squamous cell head and neck cancer treated with cetuximab
por: Magnes, T., et al.
Publicado: (2019)

Advances in T-cell checkpoint immunotherapy for head and neck squamous cell carcinoma
por: Qi, Xinmeng, et al.
Publicado: (2017)

Immune checkpoint pathways in immunotherapy for head and neck squamous cell carcinoma
por: Mei, Zi, et al.
Publicado: (2020)

Targeting LSD1 suppresses stem cell-like properties and sensitizes head and neck squamous cell carcinoma to PD-1 blockade
por: Han, Yong, et al.
Publicado: (2021)

Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons
por: Naimi, Adel, et al.
Publicado: (2022)

Author Correction: Imaging and clinical data archive for head and neck squamous cell carcinoma patients treated with radiotherapy
por: Grossberg, Aaron J., et al.
Publicado: (2018)

Disease progression status during initial immune checkpoint inhibitor (ICI) affects the clinical outcome of ICI retreatment in advanced non‐small cell lung cancer patients
por: Torasawa, Masahiro, et al.
Publicado: (2023)

Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2023)

Author Correction: A retrospective analysis of tumor infiltrating lymphocytes in head and neck squamous cell carcinoma patients treated with nivolumab
por: Kuba, Kiyomi, et al.
Publicado: (2023)

Bayesian Networks to Support Decision-Making for Immune-Checkpoint Blockade in Recurrent/Metastatic (R/M) Head and Neck Squamous Cell Carcinoma (HNSCC)
por: Huehn, Marius, et al.
Publicado: (2021)

Correction: Bintrafusp alfa, a bifunctional fusion protein targeting TGF-β and PD-L1, in advanced squamous cell carcinoma of the head and neck: results from a phase I cohort
Publicado: (2020)

Correction: Small-molecule inhibition of STAT3 in radioresistant head and neck squamous cell carcinoma
por: Bharadwaj, Uddalak, et al.
Publicado: (2019)

Correction: Expression of immunohistochemical markers in non-oropharyngeal head and neck squamous cell carcinoma in Ghana
por: Owusu-Afriyie, Osei, et al.
Publicado: (2018)

Metastatic lymph node targeted CTLA4 blockade: a potent intervention for local and distant metastases with minimal ICI-induced pneumonia
por: Mishra, Radhika, et al.
Publicado: (2023)

Interleukin-1 blockade overcomes erlotinib resistance in head and neck squamous cell carcinoma
por: Stanam, Aditya, et al.
Publicado: (2016)

[(18)F]FDG-PET accurately identifies pathological response early upon neoadjuvant immune checkpoint blockade in head and neck squamous cell carcinoma
por: Vos, Joris L., et al.
Publicado: (2021)

Overcoming Resistance to Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinomas
por: dos Santos, Lucas V., et al.
Publicado: (2021)

Long-Term Toxicities of Immune Checkpoint Inhibitor (ICI) in Melanoma Patients
por: Tong, Justin, et al.
Publicado: (2022)

Implementation of Double Immune Checkpoint Blockade Increases Response Rate to Induction Chemotherapy in Head and Neck Cancer
por: Semrau, Sabine, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_8cvf7bemk1mvlp84t15mps7bli